The development of antibody-based therapeutics for patients with acute myeloid leukemia
(AML) has long been hampered due to the shared expression of antigens on leukemic …

Simple Summary Immunotherapy may be an attractive treatment option to increase survival,
and to reduce treatment-related side effects, for children with acute myeloid leukemia (AML) …

RNA-binding proteins (RBPs) form a large and diverse class of factors, many members of
which are overexpressed in hematologic malignancies. RBPs participate in various …

Background This study aims to explore patients' with acute myeloid leukemia perceptions
about precision medicine and their preferences for involvement in this new area of shared …

Acute myeloid leukemia (AML) is a malignancy of the hematological system, for which there
remains an urgent need for new therapeutic and diagnostic targets. COMM domain …

Acute myeloid leukaemia (AML) is a malignant disease of myeloid hematopoietic
stem/progenitor cells. Despite improved understanding of the pathogenesis of AML since the …

Most of the AML patients in remission develop multidrug resistance after the first-line therapy
and relapse. AML stem cells have gained attention for their chemoresistance potentials …

Introduction Despite the approval of several new drugs, deaths from acute myeloid leukemia
(AML) remain common. Because of well-defined cell surface antigens, easy accessibility …

Leukemia is a type of blood cancer characterized by high genetic heterogeneity and fatality.
While chemotherapy remains the primary form of treatment for leukemia, its effectiveness …

As the first histone acetyltransferase to be cloned and identified in yeast, general control non-
depressible 5 (GCN5) plays a crucial role in epigenetic and chromatin modifications. It has …